Hyperthermia is one of the most powerful tools in chronic Lyme treatment. The question isn't whether to use it — it's when.
If you've been researching treatment options for chronic Lyme disease, you've probably encountered hyperthermia — specifically, systemic perfusion hyperthermia — as a headline therapy at various clinics. It sounds powerful. It is powerful. But powerful doesn't mean first.
The order in which therapies are applied isn't a minor detail. In a chronically dysregulated immune system, sequence changes everything.
What Systemic Perfusion Hyperthermia Actually Does
Systemic perfusion hyperthermia (SPH) elevates your core body temperature in a controlled clinical environment — at the Immunotherapy Institute, up to 42°C (107.6°F). At that temperature, Borrelia burgdorferi and other persistent pathogens cannot survive or replicate. It creates a whole-body environment hostile to infection, while simultaneously mobilizing immune activity and disrupting the conditions that allow bacterial persistence.
This is not a sauna. It is a precisely managed clinical procedure. And its effects on bacterial persistence and immune activation are well-documented. It's a meaningful intervention — not a gimmick — and for the right patient at the right time, it's extraordinarily effective.
The problem is the "right time" part.
The Hidden Problem of Starting with Hyperthermia
Chronic Lyme patients don't arrive with normal immune systems. They arrive with deeply dysregulated ones. Inflammation is high. Regulatory T-cell function — the immune system's off-switch — is depleted. The body is already overreacting to everything: food, stress, environmental triggers, its own tissue.
When you introduce a major immune-stimulating, pathogen-killing intervention into that environment, the immune system doesn't respond the way it would in a regulated state. Instead of mounting a targeted, proportionate response, it amplifies the existing dysfunction. Reactions can be intense. Recovery can be slower. And the gains — while real — are often less durable than they would be on a recalibrated foundation.
Think of it like renovating a house. You don't install beautiful new floors before fixing the foundation and the leaking roof. You stabilize the structure first. Then the renovation holds.
What "Cleaning the Terrain" Means Medically
Restoring Treg function — the immune system's thermostat — reduces baseline inflammation, restores appropriate immune signaling, and allows the body to mount targeted responses instead of system-wide misfires.
When that regulatory foundation is in place, subsequent therapies — including hyperthermia — work with the immune system rather than against a chaotic one. The same intervention lands differently on a regulated body. The pathogen-killing effects of hyperthermia are more targeted. The immune activation it generates is more purposeful. The recovery is more complete.
The Sequencing Philosophy at the Immunotherapy Institute
The Lyme Re-code program positions Treg apheresis first — in the 10-day program — specifically because it prepares the immune foundation for everything that follows. Patients who then want to do deeper work have the option to return for the 18-day program, which includes systemic perfusion hyperthermia (up to 42°C) and a second round of apheresis.
At that point, the immune system is no longer in the same chaotic state. The SPH works with a regulated system instead of against a dysregulated one. The apheresis removes the remaining inflammatory burden from a body that has already begun to recalibrate. The results go deeper because the body is actually ready to receive them.
This isn't about being slower or more cautious. It's about being more effective. The difference between treatment and strategic treatment.
What This Means If You're Considering a Hyperthermia-First Clinic
You're not wrong to want hyperthermia. It's a legitimate and powerful therapy. You may simply benefit most from doing it after your immune system has been recalibrated — when your body can actually use what hyperthermia offers, rather than amplifying the dysregulation it's already running on.
If you're comparing clinics and protocols, the question worth asking isn't just "do they offer hyperthermia?" It's: "at what point in the protocol does it appear, and what does the immune environment look like when it's applied?"
The answer to that question may change which program makes the most sense for where you are right now.
Shen et al. — Treg cells in Lyme arthritis (Harvard/MGH) — Arthritis & Rheumatism 2010
Frontiers in Immunology 2026 — Treg cell and gene therapy review
NEJM — Low-dose IL-2 and Treg restoration in autoimmune vasculitis
Considering hyperthermia? Talk to us first about whether your immune system is ready for it.
Gabriela Rodriguez, our Senior Patient Coordinator, will review your case and help you understand which program — and which sequence — makes the most clinical sense for where you are now.
Check My Eligibility